Double Whammy For Acucela As Otsuka Ends Alliances
This article was originally published in PharmAsia News
Executive Summary
Otsuka has terminated two licensing and development deals with Acucela in the wake of the recent Phase III failure of the US ophthalmic venture's lead pipeline molecule, prompting Acucela to delay its AGM and inversion plans.